
RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 09//85,908

Art Unit / Team No.: 0/PE

Date Processed by STIC: 1//2/98

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

ARTI SHAH 703-308-4212

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998

TIME: 17:06:06

Input Set: I185908.RAW

This Raw Listing contains the General Information Section and those Sequences containing ERRORS.

1 <110> Blaschuk, Orest W.
2 Gour, Barbara J.
3 <120> COMPOUNDS AND METHODS FOR MODULATING CLAUDIN-MEDIATED
4 FUNCTIONS
5 <130> 100086.409
6 <140> US/09/185,908
7 <141> 1998-11-03
8 <160> 269
9 <170> PatentIn Ver. 2.0
Corrected Diskette Needed

ERRORED SEQUENCES FOLLOW

37

<213> Artificial Sequence

			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
	10	<210>	59	
	11	<211>	6	
	12	<212>	PRT	
	13	<213>	Artificial Sequence	
	14	<220>		
	15	<223>	Description of Artificial Sequence: Product of	
	16		synthesis based on mouse claudin-1 sequence	
	17	<220>	( a for ena)	
	18	<223>	Cyclic Peptide	
	19	<400>	59	. 1. 1
	20		Cys Ile Tyr Ser Tyr Cys	caes,
E>	21		Description of Artificial Sequence: Product of synthesis based on mouse claudin-1 sequence  Cyclic Peptide  Cyclic Peptide  Cyclic Peptide  Tyr Ser Tyr Cys  1 5 10 Plan delete - hot need to be since less than a sun and a sequence  PRT  Artificial Sequence	-/0
	22	<210>	50 anni andi a	u
	23	<211>	7	j
	24	<212>	PRT	
	25	<213>	Artificial Sequence	
	26	<220>	-	
	27	<223>	Description of Artificial Sequence: Product of	
	28		synthesis based on mouse claudin-1 sequence	
	29	<220>	•	
	30	<223>	Cyclic Peptide	
	31	<400>	50	
	32		Cys Ile Tyr Ser Tyr Ala Cys	
E>	33		1 5 (10)	
	34	<210>	51	
	35	<211>	}	
	36	<212>	PRT	

RAW SEQUENCE LISTING DATE: 11/12/1998 PAGE: 2 TIME: 17:06:06 PATENT APPLICATION US/09/185,908 Input Set: I185908.RAW 38 <220> <223> Description of Artificial Sequence: Product of 39 synthesis based on mouse claudin-1 sequence 40 <220> 41 <223> Cyclic Peptide 42 43 <400> 61 Cys Ile Tyr Ser Tyr Ala Gly Cys 44 5 45 1 E--> <210> 62 46 47 <211> 7 48 <212> PRT 49 <213> Artificial Sequence <220> 50 <223> Description of Artificial Sequence: Product of 51 synthesis based on mouse claudin-1 sequence 52 53 <220> 54 <223> Cyclic Peptide 55 <400> 62 Cys Lys Ile Tyr Ser Tyr Cys 56 5 E--> 57 <210> 63 58 59 <211> 8 60 <212> PRT <213> Artificial Sequence 61 62 63 <223> Description of Artificial Sequence: Product of synthesis based on mouse claudin-1 sequence 64 <220> 65 <223> Cyclic Peptide 66 <400> 63 67 68 Cys Lys Ile Tyr Ser Tyr Ala Cys 1 5 E--> 69 70 <210> 64 <211> 9 71 72 <212> PRT

82 <210> 65

<220>

<220>

<400> 64

73 74

75

76 77

78

79

80

81

E-->

<213> Artificial Sequence

<223> Cyclic Peptide

<223> Description of Artificial Sequence: Product of
 synthesis based on mouse claudin-1 sequence

Cys Lys Ile Tyr Ser Tyr Ala Gly Cys

5

83 <211> 8

DATE: 11/12/1998 RAW SEQUENCE LISTING PAGE: 3 PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 84 <212> PRT 85 <213> Artificial Sequence 86 <220> <223> Description of Artificial Sequence: Product of 87 88 synthesis based on mouse claudin-1 sequence 89 <220> <223> Cyclic Peptide 90 <400> 65 91 Cys Trp Lys Ile Tyr Ser Tyr Cys 92 93 E--> <210> 66 94 95 <211> 9 <212> PRT 96 97 <213> Artificial Sequence 98 <220> 99 <223> Description of Artificial Sequence: Product of synthesis based on mouse claudin-1 sequence 100 <220> 101 <223> Cyclic Peptide 102 103 <400> 66 Cys Trp Lys Ile Tyr Ser Tyr Ala Cys 104 105 <210> 68 106 <211> 6 107 108 <212> PRT <213> Artificial Sequence 109 110 <220> <223> Description of Artificial Sequence: Product of 111 synthesis based on mouse claudin-1 sequence 112 113 <220> <223> Cyclic Peptide 114 <400> 68 115 116 Lys Ile Tyr Ser Tyr Asp 117 5 E--> 1 <210> 69 118 119 <211> 7 120 <212> PRT 121 <213> Artificial Sequence 122 <220> <223> Description of Artificial Sequence: Product of 123 synthesis based on mouse claudin-1 sequence 124 125 <220> <223> Cyclic Peptide 126 127 <400> 69

130 <210> 70

Lys Ile Tyr Ser Tyr Ala Asp

128

129

E-->

DATE: 11/12/1998

PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 131 <211> 8 132 <212> PRT 133 <213> Artificial Sequence <220> 134 <223> Description of Artificial Sequence: Product of 135 synthesis based on mouse claudin-1 sequence 136 137 <220> 138 <223> Cyclic Peptide 139 <400> 70 Lys Ile Tyr Ser Tyr Ala Gly Asp 140 E--> 141 142 <210> 71 143 <211> 7 144 <212> PRT <213> Artificial Sequence 145 146 <220> <223> Description of Artificial Sequence: Product of 147 synthesis based on mouse claudin-1 sequence 148 149 <220> 150 <223> Cyclic Peptide <400> 71 151 152 Lys Lys Ile Tyr Ser Tyr Asp E--> 153 1 5 154 <210> 72 155 <211> 8 156 <212> PRT 157 <213> Artificial Sequence 158 <220> 159 <223> Description of Artificial Sequence: Product of 160 synthesis based on mouse claudin-1 sequence 161 <220> <223> Cyclic Peptide 162 163 <400> 72 164 Lys Lys Ile Tyr Ser Tyr Ala Asp E--> 165 5 166 <210> 73 167 <211> 9 168 <212> PRT 169 <213> Artificial Sequence 170 171 <223> Description of Artificial Sequence: Product of 172 synthesis based on mouse claudin-1 sequence 173 <220> 174 <223> Cyclic Peptide 175 <400> 73 176 Lys Lys Ile Tyr Ser Tyr Ala Gly Asp E--> 177 1

RAW SEQUENCE LISTING

PAGE:

4

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

TIME: 17:06:06

DATE: 11/12/1998

```
<210> 74
       178
       179
              <211> 8
       180
              <212> PRT
       181
             <213> Artificial Sequence
       182
       183
              <223> Description of Artificial Sequence: Product of
       184
                    synthesis based on mouse claudin-1 sequence
              <220>
       185
       186
              <223> Cyclic Peptide
              <400> 74
       187
       188
                    Lys Trp Lys Ile Tyr Ser Tyr Asp
E-->
       189
       190
             <210> 75
             <211> 9
       191
       192
             <212> PRT
       193
             <213> Artificial Sequence
       194
             <220>
       195
              <223> Description of Artificial Sequence: Product of
       196
                    synthesis based on mouse claudin-1 sequence
       197
             <220>
       198
             <223> Cyclic Peptide
       199
             <400> 75
       200
                    Lys Trp Lys Ile Tyr Ser Tyr Ala Asp
       201
E-->
       202
             <210> 77
       203
             <211> 6
       204
             <212> PRT
       205
             <213> Artificial Sequence
       206
             <220>
       207
             <223> Description of Artificial Sequence: Product of
       208
                    synthesis based on mouse claudin-1 sequence
       209
             <220>
       210
             <223> Cyclic Peptide
       211
             <400> 77
       212
                   Lys Ile Tyr Ser Tyr Glu
       213
E-->
       214
             <210> 78
       215
             <211> 7
       216
             <212> PRT
       217
             <213> Artificial Sequence
       218
       219
             <223> Description of Artificial Sequence: Product of
       220
                   synthesis based on mouse claudin-1 sequence
       221
             <220>
       222
             <223> Cyclic Peptide
       223
             <400> 78
```

### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908 TIME: 17:06:06

DATE: 11/12/1998

			input Set: 1165906.RAW
	224		Ive Ile The Sec The No Clu
E>	224 <b>225</b>		Lys Ile Tyr Ser Tyr Ala Glu  1  5
	226	<210>	79
	227	<211>	
	228	<212>	
	229		Artificial Sequence
	230	<220>	<del>-</del>
	231		Description of Artificial Sequence: Product of
	232		synthesis based on mouse claudin-1 sequence
	233	<220>	- · · · · · · · · · · · · · · · · · · ·
	234		Cyclic Peptide
	235	<400>	
	236	(400)	Lys Ile Tyr Ser Tyr Ala Gly Glu
E>	237		1 5 (10)
	238	<210>	80
	239	<211>	
	240	<212>	
	241		Artificial Sequence
	242	<220>	
	243		Description of Artificial Sequence: Product of
	244	(223)	synthesis based on mouse claudin-1 sequence
	245	<220>	
	246		Cyclic Peptide
	247	<400>	
	248	(400)	Lys Lys Ile Tyr Ser Tyr Glu
R>	249		1 5 (10)
	250	<210>	81
	251	<211>	8
	252	<212>	PRT
	253	<213>	Artificial Sequence
	254	<220>	<del>-</del>
	255	<223>	Description of Artificial Sequence: Product of
	256		synthesis based on mouse claudin-1 sequence
	257	<220>	-
	258		Cyclic Peptide
	259	<400>	
	260		Lys Lys Ile Tyr Ser Tyr Ala Glu
E>	261		1 5 (10)
	262	<210>	82
	263	<211>	9
	264	<212>	PRT
	265		Artificial Sequence
	266	<220>	<del>-</del>
	267		Description of Artificial Sequence: Product of
	268		synthesis based on mouse claudin-1 sequence
	269	<220>	• 4

PAGE: 7 RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

Input Set: I185908.RAW

DATE: 11/12/1998

TIME: 17:06:06

```
270
             <223> Cyclic Peptide
       271
             <400> 82
                    Lys Lys Ile Tyr Ser Tyr Ala Gly Glu
       272
E-->
       273
             <210> 83
       274
       275
             <211> 8
             <212> PRT
       276
             <213> Artificial Sequence
       277
       278
             <220>
             <223> Description of Artificial Sequence: Product of
       279
                    synthesis based on mouse claudin-1 sequence
       280
       281
             <220>
       282
             <223> Cyclic Peptide
       283
             <400> 83
       284
                    Lys Trp Lys Ile Tyr Ser Tyr Glu
                                       5
E-->
       285
             <210> 84
       286
       287
             <211> 9
             <212> PRT
       288
       289
             <213> Artificial Sequence
       290
             <220>
       291
             <223> Description of Artificial Sequence: Product of
                    synthesis based on mouse claudin-1 sequence
       292
       293
             <220>
       294
             <223> Cyclic Peptide
       295
             <400> 84
       296
                    Lys Trp Lys Ile Tyr Ser Tyr Ala Glu
       297
                                       5
E-->
       298
             <210> 86
       299
             <211> 6
       300
             <212> PRT
       301
             <213> Artificial Sequence
       302
             <220>
             <223> Description of Artificial Sequence: Product of
       303
                    synthesis based on mouse claudin-1 sequence
       304
       305
             <220>
       306
             <223> Cyclic Peptide
       307
             <400> 86
                    Asp Ile Tyr Ser Tyr Lys
       308
E-->
       309
                                       5
             <210> 87
       310
       311
             <211> 7
       312
             <212> PRT
       313
             <213> Artificial Sequence
       314
             <223> Description of Artificial Sequence: Product of
       315
```

PAGE: 8 RAW SEQUENCE LISTING DATE: 11/12/1998
PATENT APPLICATION US/09/185,908 TIME: 17:06:06

```
synthesis based on mouse claudin-1 sequence
       316
       317
              <220>
       318
              <223> Cyclic Peptide
              <400> 87
       319
                    Asp Ile Tyr Ser Tyr Ala Lys
       320
       321
                                       5
E-->
              <210> 88
       322
              <211> 8
       323
       324
              <212> PRT
              <213> Artificial Sequence
       325
       326
              <220>
       327
              <223> Description of Artificial Sequence: Product of
       328
                    synthesis based on mouse claudin-1 sequence
       329
              <220>
       330
              <223> Cyclic Peptide
       331
              <400> 88
                    Asp Ile Tyr Ser Tyr Ala Gly Lys
       332
                                       5
E-->
       333
                      1
       334
              <210> 89
              <211> 7
       335
       336
              <212> PRT
       337
              <213> Artificial Sequence
       338
              <220>
              <223> Description of Artificial Sequence: Product of
       339
                    synthesis based on mouse claudin-1 sequence
       340
              <220>
       341
              <223> Cyclic Peptide
       342
       343
              <400> 89
       344
                    Asp Lys Ile Tyr Ser Tyr Lys
B-->
       345
                                       5
       346
             <210> 90
       347
              <211> 8
       348
             <212> PRT
       349
             <213> Artificial Sequence
       350
              <220>
       351
             <223> Description of Artificial Sequence: Product of
       352
                    synthesis based on mouse claudin-1 sequence
       353
             <220>
       354
             <223> Cyclic Peptide
       355
              <400> 90
       356
                    Asp Lys Ile Tyr Ser Tyr Ala Lys
                                       5
E-->
       357
       358
             <210> 91
       359
             <211> 9
             <212> PRT
       360
       361
             <213> Artificial Sequence
```

PAGE: 9 RAW SEQUENCE LISTING DATE: 11/12/1998 PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 362 <220> <223> Description of Artificial Sequence: Product of 363 synthesis based on mouse claudin-1 sequence 364 365 <220> 366 <223> Cyclic Peptide 367 <400> 91 Asp Lys Ile Tyr Ser Tyr Ala Gly Lys 368 E--> 369 370 <210> 92 371 <211> 8 372 <212> PRT 373 <213> Artificial Sequence 374 <220> 375 <223> Description of Artificial Sequence: Product of 376 synthesis based on mouse claudin-1 sequence 377 <220> 378 <223> Cyclic Peptide 379 <400> 92 380 Asp Trp Lys Ile Tyr Ser Tyr Lys E--> 381 5 382 <210> 93 <211> 9 383 <212> PRT 384 385 <213> Artificial Sequence 386 387 <223> Description of Artificial Sequence: Product of 388 synthesis based on mouse claudin-1 sequence 389 <220> 390 <223> Cyclic Peptide 391 <400> 93 392 Asp Trp Lys Ile Tyr Ser Tyr Ala Lys 393 5 <210> 95 394 <211> 6 395 396 <212> PRT 397 <213> Artificial Sequence 398 <220> 399 <223> Description of Artificial Sequence: Product of 400 synthesis based on mouse claudin-1 sequence

406 <210> 96

<220>

<400> 95

<223> Cyclic Peptide

Glu Ile Tyr Ser Tyr Lys

5

401

402

403

404

405

E-->

407 <211> 7

TIME: 17:06:06

PAGE: 10 RAW SEQUENCE LISTING DATE: 11/12/1998

PATENT APPLICATION US/09/185,908

```
408
              <212> PRT
       409
              <213> Artificial Sequence
       410
              <223> Description of Artificial Sequence: Product of
       411
       412
                    synthesis based on mouse claudin-1 sequence
              <220>
       413
       414
              <223> Cyclic Peptide
       415
              <400> 96
       416
                    Glu Ile Tyr Ser Tyr Ala Lys
       417
                                       5
              <210> 97
       418
       419
              <211> 8
       420
              <212> PRT
       421
              <213> Artificial Sequence
       422
              <220>
       423
              <223> Description of Artificial Sequence: Product of
                    synthesis based on mouse claudin-1 sequence
       424
       425
              <220>
       426
              <223> Cyclic Peptide
       427
              <400> 97
       428
                    Glu Ile Tyr Ser Tyr Ala Gly Lys
       429
                                       5
E-->
       430
              <210> 98
       431
              <211> 7
       432
              <212> PRT
       433
              <213> Artificial Sequence
       434
       435
              <223> Description of Artificial Sequence: Product of
       436
                    synthesis based on mouse claudin-1 sequence
       437
              <220>
       438
              <223> Cyclic Peptide
       439
              <400> 98
       440
                    Glu Lys Ile Tyr Ser Tyr Lys
       441
              <210> 99
       442
       443
              <211> 8
       444
              <212> PRT
       445
              <213> Artificial Sequence
       446
              <220>
       447
              <223> Description of Artificial Sequence: Product of
       448
                    synthesis based on mouse claudin-1 sequence
       449
              <220>
              <223> Cyclic Peptide
       450
       451
              <400> 99
       452
                    Glu Lys Ile Tyr Ser Tyr Ala Lys
       453
                      1
                                       5
E-->
       454
              <210> 100
```

PAGE: 11 RAW SEQUENCE LISTING DATE: 11/12/1998

PATENT APPLICATION US/09/185,908

Input Set: I185908.RAW

TIME: 17:06:06

455 <211> 9 <212> PRT 456 457 <213> Artificial Sequence 458 <220> 459 <223> Description of Artificial Sequence: Product of synthesis based on mouse claudin-1 sequence 460 461 <220> 462 <223> Cyclic Peptide <400> 100 463 Glu Lys Ile Tyr Ser Tyr Ala Gly Lys 464 465 E--> 466 <210> 101 467 <211> 8 468 <212> PRT 469 <213> Artificial Sequence 470 <220> 471 <223> Description of Artificial Sequence: Product of synthesis based on mouse claudin-1 sequence 472 473 <220> 474 <223> Cyclic Peptide 475 <400> 101 476 Glu Trp Lys Ile Tyr Ser Tyr Lys 477 5 E--> <210> 102 478 479 <211> 9 <212> PRT 480 481 <213> Artificial Sequence 482 <220> 483 <223> Description of Artificial Sequence: Product of 484 synthesis based on mouse claudin-1 sequence 485 <220> 486 <223> Cyclic Peptide 487 <400> 102 488 Glu Trp Lys Ile Tyr Ser Tyr Ala Lys E--> 489 5 490 <210> 104 491 <211> 5 492 <212> PRT 493 <213> Artificial Sequence 494 <220> 495 <223> Description of Artificial Sequence: Product of 496 synthesis based on mouse claudin-1 sequence 497 <220> 498 <223> Cyclic Peptide 499 <400> 104 500 Ile Tyr Ser Tyr Ala E--> 501 1 5

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

```
502
              <210> 105
       503
              <211> 6
       504
              <212> PRT
       505
              <213> Artificial Sequence
       506
              <220>
       507
              <223> Description of Artificial Sequence: Product of
       508
                    synthesis based on mouse claudin-1 sequence
       509
              <220>
       510
              <223> Cyclic Peptide
              <400> 105
       511
       512
                    Ile Tyr Ser Tyr Ala Gly
E-->
       513
              <210> 106
       514
       515
              <211> 5
       516
              <212> PRT
             <213> Artificial Sequence
       517
              <220>
       518
              <223> Description of Artificial Sequence: Product of
       519
       520
                    synthesis based on mouse claudin-1 sequence
       521
              <220>
       522
             <223> Cyclic Peptide
       523
              <400> 106
       524
                    Lys Ile Tyr Ser Tyr
E-->
       525
                      1
                                       5
             <210> 107
       526
       527
             <211> 7
       528
             <212> PRT
       529
             <213> Artificial Sequence
       530
             <223> Description of Artificial Sequence: Product of
       531
       532
                    synthesis based on mouse claudin-1 sequence
       533
             <220>
       534
             <223> Cyclic Peptide
       535
             <400> 107
       536
                    Lys Ile Tyr Ser Tyr Ala Gly
       537
                                       5
E-->
                      1
             <210> 108
       538
       539
             <211> 6
       540
             <212> PRT
       541
             <213> Artificial Sequence
       542
             <220>
       543
             <223> Description of Artificial Sequence: Product of
       544
                    synthesis based on mouse claudin-1 sequence
       545
             <220>
       546
             <223> Cyclic Peptide
             <400> 108
       547
```

### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

		Impac BCC. 1105500.RA
	548	Missa I via Tila Maria Gara Maria
E>	549	Trp Lys Ile Tyr Ser Tyr  1 5 (10)
	243	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
	550	<210> 109
	551	<211> 7
	552	<212> PRT
	553	<213> Artificial Sequence
	554	<220>
	555	<223> Description of Artificial Sequence: Product of
	556	
	557	synthesis based on mouse claudin-1 sequence <220>
	558	<223> Cyclic Peptide
	559	<400> 109
	560	
E>	561	Trp Lys Ile Tyr Ser Tyr Ala
6>	201	1 5 (10)
	562	<210> 110
	562 563	<210> 110 <211> 8
	564	<211> 8 <212> PRT
	565	
	566	<213> Artificial Sequence <220>
	567	
	568	<223> Description of Artificial Sequence: Product of
	569	synthesis based on mouse claudin-1 sequence <220>
	570 571	<223> Cyclic Peptide
	571 572	<400> 110
₽	573	Trp Lys Ile Tyr Ser Tyr Ala Gly
		1 5 (10)
	574	<210> 111
	575	<211> 6
	576	<212> PRT
	577	<213> Artificial Sequence
	578	<220>
	579	<223> Description of Artificial Sequence: Product of
	580	synthesis based on mouse claudin-2 sequence
	581	<220>
	582	<223> Cyclic Peptide
	583	<400> 111 \
	584	Cys Thr Ser Ser Tyr Cys
E>	585	1 5 (10)
	586	<210> 112
	587	<211> 7
	588	<212> PRT
	589	<213> Artificial Sequence
	590	<220>
	591	<pre>&lt;223&gt; Description of Artificial Sequence: Product of</pre>
	592	synthesis based on mouse claudin-2 sequence
	593	<pre>column</pre>

PAGE: 14 RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

			•
	594	<223>	Cyclic Peptide
	595	<400>	
	596		Cys Thr Ser Ser Tyr Val Cys
E>	597		1 5 (10)
	598	<210>	113
	599	<211>	
	600	<212>	
	601		Artificial Sequence
	602	<220>	
	603		Description of Artificial Sequence: Product of
	604		synthesis based on mouse claudin-2 sequence
	605	<220>	
	606		Cyclic Peptide
	607	<400>	
	608		Cys Thr Ser Ser Tyr Val Gly Cys
E>	609		1 5 (10)
		010	V
	610	<210>	·
	611	<211>	
	612	<212>	
	613		Artificial Sequence
	614	<220>	
	615	<223>	Description of Artificial Sequence: Product of
	616 617	<220>	synthesis based on mouse claudin-2 sequence
			Consider Production
	618 619	<223> <400>	Cyclic Peptide
	620	<400>	
E>	621		Cys Arg Thr Ser Ser Tyr Cys  1  5
			<u> </u>
	622	<210>	115
	623	<211>	8
	624	<212>	PRT
	625	<213>	Artificial Sequence
	626	<220>	
	627	<223>	Description of Artificial Sequence: Product of
	628		synthesis based on mouse claudin-2 sequence
	629	<220>	
	630	<223>	Cyclic Peptide
	631	<400>	115
	632		Cys Arg Thr Ser Ser Tyr Val Cys
E>	633		1 5 $\left(10\right)^{1}$
	634	<210>	116
	635	<211>	
	636	<212>	
	637		Artificial Sequence
	638	<220>	
	639		Description of Artificial Sequence: Product of

PAGE: 15 RAW SEQUENCE LISTING DATE: 11/12/1998 PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 640 synthesis based on mouse claudin-2 sequence 641 <220> 642 <223> Cyclic Peptide 643 <400> 116 644 Cys Arg Thr Ser Ser Tyr Val Gly Cys E--> 645 5 646 <210> 117 647 <211> 8 648 <212> PRT 649 <213> Artificial Sequence 650 <220> <223> Description of Artificial Sequence: Product of 651 652 synthesis based on mouse claudin-2 sequence 653 <220> 654 <223> Cyclic Peptide 655 <400> 117 656 Cys Trp Arg Thr Ser Ser Tyr Cys E--> 657 5 658 <210> 118 659 <211> 9 660 <212> PRT 661 <213> Artificial Sequence 662 <220> 663 <223> Description of Artificial Sequence: Product of 664 synthesis based on mouse claudin-2 sequence 665 <220> 666 <223> Cyclic Peptide 667 <400> 118 668 Cys Trp Arg Thr Ser Ser Tyr Val Cys E--> 669 5 670 <210> 120 671 <211> 6 672 <212> PRT 673 <213> Artificial Sequence 674 <220> 675 <223> Description of Artificial Sequence: Product of 676 synthesis based on mouse claudin-2 sequence 677 <220> <223> Cyclic Peptide 678 679 <400> 120 680 Lys Thr Ser Ser Tyr Asp

682 <210> 121

683 <211> 7

681

E-->

684 <212> PRT

685 <213> Artificial Sequence

5

PAGE: 16 RAW SEQUENCE LISTING DATE: 11/12/1998 PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 686 <220> 687 <223> Description of Artificial Sequence: Product of 688 synthesis based on mouse claudin-2 sequence 689 <220> <223> Cyclic Peptide 690 691 <400> 121 692 Lys Thr Thr Ser Tyr Val Asp E--> 693 694 <210> 122 695 <211> 8 696 <212> PRT 697 <213> Artificial Sequence 698 <220> 699 <223> Description of Artificial Sequence: Product of 700 synthesis based on mouse claudin-2 sequence 701 <220> 702 <223> Cyclic Peptide 703 <400> 122 704 Lys Thr Thr Ser Tyr Val Gly Asp E--> 705 5 706 <210> 123 707 <211> 7 708 <212> PRT 709 <213> Artificial Sequence 710 <220> 711 <223> Description of Artificial Sequence: Product of 712 synthesis based on mouse claudin-2 sequence 713 <220> 714 <223> Cyclic Peptide 715 <400> 123 716 Lys Arg Thr Ser Ser Tyr Asp 717 1 5 718 <210> 124 719 <211> 8 720 <212> PRT 721 <213> Artificial Sequence 722 <220> 723 <223> Description of Artificial Sequence: Product of 724 synthesis based on mouse claudin-2 sequence 725 <220> 726 <223> Cyclic Peptide 727 <400> 124 728 Lys Arg Thr Ser Ser Tyr Val Asp E--> 729 5

730 <210> 125

731 <211> 9

PAGE: 17 RAW SEQUENCE LISTING DATE: 11/12/1998
PATENT APPLICATION US/09/185,908 TIME: 17:06:06

Input Set: I185908.RAW

```
732
              <212> PRT
        733
              <213> Artificial Sequence
        734
        735
              <223> Description of Artificial Sequence: Product of
        736
                    synthesis based on mouse claudin-2 sequence
        737
              <220>
        738
              <223> Cyclic Peptide
        739
              <400> 125
        740
                    Lys Arg Thr Ser Ser Tyr Val Gly Asp
E-->
        741
        742
              <210> 126
        743
              <211> 8
        744
              <212> PRT
        745
              <213> Artificial Sequence
        746
              <220>
        747
              <223> Description of Artificial Sequence: Product of
        748
                    synthesis based on mouse claudin-2 sequence
        749
              <220>
        750
              <223> Cyclic Peptide
        751
              <400> 126
       752
                    Lys Trp Arg Thr Ser Ser Tyr Asp
E-->
       753
       754
              <210> 127
       755
              <211> 9
       756
              <212> PRT
       757
              <213> Artificial Sequence
       758
              <220>
       759
              <223> Description of Artificial Sequence: Product of
       760
                    synthesis based on mouse claudin-2 sequence
       761
              <220>
       762
             <223> Cyclic Peptide
       763
             <400> 127
       764
                    Lys Trp Arg Thr Ser Ser Tyr Val Asp
E-->
       765
       766
             <210> 129
       767
             <211> 6
       768
             <212> PRT
       769
             <213> Artificial Sequence
       770
       771
             <223> Description of Artificial Sequence: Product of
       772
                   synthesis based on mouse claudin-2 sequence
       773
             <220>
       774
             <223> Cyclic Peptide
       775
             <400> 129
       776
                   Lys Thr Ser Ser Tyr Glu
E-->
       777
                     1
                                      5
```

778

<210> 130

OIPE PAGE: 18 RAW SEQUENCE LISTING DATE: 11/12/1998 PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 779 <211> 7 780 <212> PRT 781 <213> Artificial Sequence 782 <220> <223> Description of Artificial Sequence: Product of 783 784 synthesis based on mouse claudin-2 sequence 785 <220> 786 <223> Cyclic Peptide 787 <400> 130 788 Lys Thr Ser Ser Tyr Val Glu E--> 789 790 <210> 131 791 <211> 8 792 <212> PRT 793 <213> Artificial Sequence 794 <220> <223> Description of Artificial Sequence: Product of 795 796 synthesis based on mouse claudin-2 sequence 797 <220> <223> Cyclic Peptide 798 799 <400> 131 800 Lys Thr Ser Ser Tyr Val Gly Glu E--> 801 5 802 <210> 132 803 <211> 7 804 <212> PRT 805 <213> Artificial Sequence 806 807 <223> Description of Artificial Sequence: Product of 808 synthesis based on mouse claudin-2 sequence 809 <220> 810 <223> Cyclic Peptide 811 <400> 132 812 Lys Arg Thr Ser Ser Tyr Glu E--> 813 5

814 <210> 133 815 <211> 8 816 <212> PRT 817 <213> Artificial Sequence 818 <220> 819 <223> Description of Artificial Sequence: Product of 820 synthesis based on mouse claudin-2 sequence 821 <220> 822 <223> Cyclic Peptide 823 <400> 133 824 Lys Arg Thr Ser Ser Tyr Val Glu

5

825

1

B-->

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

```
826
              <210> 134
       827
              <211> 9
       828
              <212> PRT
       829
              <213> Artificial Sequence
       830
              <220>
              <223> Description of Artificial Sequence: Product of
       831
       832
                    synthesis based on mouse claudin-2 sequence
              <220>
       833
       834
              <223> Cyclic Peptide
       835
              <400> 134
       836
                    Lys Arg Thr Ser Ser Tyr Val Gly Glu
E-->
       837
                                       5
       838
              <210> 135
       839
              <211> 8
       840
              <212> PRT
       841
              <213> Artificial Sequence
       842
              <220>
       843
              <223> Description of Artificial Sequence: Product of
       844
                    synthesis based on mouse claudin-2 sequence
       845
              <220>
       846
             <223> Cyclic Peptide
       847
              <400> 135
       848
                    Lys Trp Arg Thr Ser Ser Tyr Glu
E-->
       849
                                       5
       850
             <210> 136
       851
             <211> 9
       852
             <212> PRT
       853
             <213> Artificial Sequence
       854
             <223> Description of Artificial Sequence: Product of
       855
       856
                    synthesis based on mouse claudin-2 sequence
       857
             <220>
       858
             <223> Cyclic Peptide
       859
             <400> 136
       860
                   Lys Trp Arg Thr Ser Ser Tyr Val Glu
E-->
       861
                                      5
       862
             <210> 138
       863
             <211> 6
             <212> PRT
       864
       865
             <213> Artificial Sequence
       866
             <220>
       867
             <223> Description of Artificial Sequence: Product of
       868
                   synthesis based on mouse claudin-2 sequence
       869
             <220>
       870
             <223> Cyclic Peptide
       871
             <400> 138
```

## RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

					•	
	872		Asp Thr Ser Se:	r Tyr Lys	$\wedge$ )	
E>	873		1	5	(19	
					V	
	874	<210>				
	875	<211>				
	876	<212>				
	877		· Artificial Seq	uence		
	878	<220>				
	879	<223>		_	ence: Product of	
	880			d on mouse claudi	in-2 sequence	
	881	<220>				
	882		Cyclic Peptide			
	883	<400>			1	
	884		Asp Thr Ser Ser	r Tyr Val Lys	$\bigcap$	
E>	885		1	5	40 F	
	006	212			V	
	886	<210>				
	887	<211>				
	888	<212>				
	889		Artificial Sequ	ience		
	890	<220>				
	891	<223>			ence: Product of	
	892	-000		d on mouse claudi	in-2 sequence	
	893	<220>				
	894		Cyclic Peptide			
	895 896	<400>				
₽>	897		1	Tyr Val Gly Lys 5	$\left( \begin{array}{c} 1 \\ 1 \end{array} \right)$	
				<u> </u>		
	898	<210>	141			
	899	<211>	7			
	900	<212>	PRT			
	901	<213>	Artificial Sequ	ence		
	902	<220>	•			
	903	<223>	Description of	Artificial Segue	ence: Product of	
	904			on mouse claudi		
	905	<220>	_			
	906		Cyclic Peptide			
	907	<400>				
	908		Asp Arg Thr Ser	Ser Tyr Lys	$\circ$ $\downarrow$	
E>	909		1	5	(10)	
					U	
	910	<210>	142			
	911	<211>	8			
	912	<212>	PRT			
	913	<213>	Artificial Sequ	ence		
	914	<220>	-			
	915	<223>	Description of .	Artificial Seque	nce: Product of	
	916			on mouse claudin		
	917	<220>			-	

PAGE: 21 RAW SEQUENCE LISTING DATE: 11/12/1998
PATENT APPLICATION US/09/185,908 TIME: 17:06:06

```
<223> Cyclic Peptide
        919
              <400> 142
        920
                    Asp Arg Thr Ser Ser Tyr Val Lys
E-->
        921
                                       5
        922
              <210> 143
        923
              <211> 9
        924
              <212> PRT
        925
              <213> Artificial Sequence
        926
              <220>
              <223> Description of Artificial Sequence: Product of
        927
        928
                    synthesis based on mouse claudin-2 sequence
        929
              <220>
       930
              <223> Cyclic Peptide
       931
              <400> 143
       932
                    Asp Arg Thr Ser Ser Tyr Val Gly Lys
       933
                                       5
       934
              <210> 144
       935
              <211> 8
       936
              <212> PRT
       937
              <213> Artificial Sequence
       938
              <220>
              <223> Description of Artificial Sequence: Product of
       939
       940
                    synthesis based on mouse claudin-2 sequence
       941
             <220>
       942
             <223> Cyclic Peptide
       943
             <400> 144
       944
                    Asp Trp Arg Thr Ser Ser Tyr Lys
       945
E-->
                                       5
       946
             <210> 145
       947
             <211> 9
       948
             <212> PRT
       949
             <213> Artificial Sequence
       950
             <220>
       951
             <223> Description of Artificial Sequence: Product of
       952
                    synthesis based on mouse claudin-2 sequence
       953
             <220>
       954
             <223> Cyclic Peptide
       955
             <400> 145
       956
                   Asp Trp Arg Thr Ser Ser Tyr Val Lys
E-->
       957
       958
             <210> 147
       959
             <211> 6
       960
             <212> PRT
       961
             <213> Artificial Sequence
       962
             <220>
       963
             <223> Description of Artificial Sequence: Product of
```

PAGE: 22 RAW SEQUENCE LISTING DATE: 11/12/1998 TIME: 17:06:06

PATENT APPLICATION US/09/185,908

						Input Set:	I185908.RA
	964	sv	nthesis bas	ed on mouse cla	udin-2 sequence		
	965	<220>			2 ocquence		
	966		clic Peptid	le			
	967	<400> 14	_	.0	O		
	968		u Thr Ser S	er Tur Ive	$\sim 1$		
E>	969		1	5	har		
	970	<210> 14	8				
	971	<211> 7					
	972	<212> PR					
	973		tificial Se	quence			
	974	<220>					
	975	<223> De	scription o	f Artificial Sec	quence: Product o	f	
	976		nthesis bas	ed on mouse cla	ıdin-2 sequence		
	977	<220>			_		
	978	<223> Cy	clic Peptid	e			
	979	<400> 14	8				
	980	Gl:	a Thr Ser S	er Tyr Val Lys	$\wedge$ )		
E>	981		1	5	(10)		
	982	<210> 14	<u> </u>		$\overline{}$		
	983	<211> 8	,				
	984	<211> 0	r				
	985		tificial Sec	m10000			
	986	<220>	TITCIAL Sec	quence			
	987		carintian a	f Amtificial Cas	quence: Product of	÷	
	988	\2237 De:	thesis base	ed on mouse clau	quence: Product of	5	
	989	<220>	ichesis base	ed on mouse clat	idin-2 sequence		
	990		clic Peptide	_			
	991	<400> 149	_	5			
	992			er Tyr Val Gly I	0 1		
3>	993			5	(10)		
	004	-010- 150					
	994 995	<210> 150	,				
		<211> 7					
	996 997	<212> PR7					
	997 998		ificial Sec	luence			
	998	<220>					
					uence: Product of		
	1000 1001		tinesis base	ed on mouse clau	ain-2 sequence		
		<220>	olda manada				
	1002	_	lic Peptide	2			
	1003	<400> 150			- ·		
1 -	1004			er Ser Tyr Lys	$\bigcap$		
>	1005	1		5 	(10)		
	1006	<210> 151					
	1007	<211> 8					
	1008	<212> PRT	ı				
	1009		ificial Seq				

PAGE: 23 RAW SEQUENCE LISTING DATE: 11/12/1998 PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 1010 <220> <223> Description of Artificial Sequence: Product of 1011 synthesis based on mouse claudin-2 sequence 1012 1013 <220> 1014 <223> Cyclic Peptide 1015 <400> 151 1016 Glu Arg Thr Ser Ser Tyr Val Lys 1017 E--> 5 1018 <210> 152 1019 <211> 9 1020 <212> PRT 1021 <213> Artificial Sequence <220> 1022 1023 <223> Description of Artificial Sequence: Product of synthesis based on mouse claudin-2 sequence 1024 1025 <220> 1026 <223> Cyclic Peptide 1027 <400> 152 Glu Arg Thr Ser Ser Tyr Val Gly Lys 1028 E--> 1029 1030 <210> 153 1031 <211> 8 1032 <212> PRT <213> Artificial Sequence 1033 1034 <220> 1035 <223> Description of Artificial Sequence: Product of 1036 synthesis based on mouse claudin-2 sequence 1037 <220> 1038 <223> Cyclic Peptide 1039 <400> 153 1040 Glu Trp Arg Thr Ser Ser Tyr Lys 1041 1042 <210> 154 1043 <211> 9 1044 <212> PRT 1045 <213> Artificial Sequence 1046 <220> 1047 <223> Description of Artificial Sequence: Product of 1048 synthesis based on mouse claudin-2 sequence 1049 <220> 1050 <223> Cyclic Peptide 1051 <400> 154

Glu Trp Arg Thr Ser Ser Tyr Val Lys

5

1054 <210> 156 1055 <211> 5

1052

1053

PAGE: DATE: 11/12/1998 24 RAW SEQUENCE LISTING TIME: 17:06:06

PATENT APPLICATION US/09/185,908

```
1056
             <212> PRT
      1057
             <213> Artificial Sequence
      1058
             <220>
             <223> Description of Artificial Sequence: Product of
      1059
                    synthesis based on mouse claudin-2 sequence
      1060
      1061
             <220>
      1062
             <223> Cyclic Peptide
      1063
             <400> 156
      1064
                   Thr Ser Ser Tyr Val
E-->
     1065
             <210> 157
      1066
      1067
             <211> 6
      1068
             <212> PRT
      1069
             <213> Artificial Sequence
      1070
             <220>
             <223> Description of Artificial Sequence: Product of
      1071
      1072
                    synthesis based on mouse claudin-2 sequence
      1073
             <220>
             <223> Cyclic Peptide
      1074
      1075
             <400> 157
      1076
                   Thr Ser Ser Tyr Val Gly
E--> 1077
      1078
             <210> 158
      1079
             <211> 5
      1080
             <212> PRT
      1081
             <213> Artificial Sequence
      1082
             <220>
             <223> Description of Artificial Sequence: Product of
      1083
                   synthesis based on mouse claudin-2 sequence
      1084
      1085
             <220>
      1086
             <223> Cyclic Peptide
      1087
             <400> 158
                   Arg Thr Ser Ser Tyr
      1088
      1089
                                      5
      1090
             <210> 159
      1091
             <211> 6
      1092
             <212> PRT
      1093
             <213> Artificial Sequence
      1094
      1095
             <223> Description of Artificial Sequence: Product of
      1096
                   synthesis based on mouse claudin-2 sequence
      1097
             <220>
      1098
             <223> Cyclic Peptide
     1099
             <400> 159
      1100
                   Arg Thr Ser Ser Tyr Val
     1101
                     1
                                      5
```

PAGE: 25 RAW SEQUENCE LISTING DATE: 11/12/1998 TIME: 17:06:06

PATENT APPLICATION US/09/185,908

```
<211> 7
      1103
      1104
             <212> PRT
      1105
             <213> Artificial Sequence
             <220>
      1106
      1107
             <223> Description of Artificial Sequence: Product of
      1108
                    synthesis based on mouse claudin-2 sequence
             <220>
      1109
      1110
             <223> Cyclic Peptide
             <400> 160
      1111
      1112
                   Arg Thr Ser Ser Tyr Val Gly
E--> 1113
                                      5
             <210> 161
      1114
             <211> 6
      1115
      1116
             <212> PRT
      1117
             <213> Artificial Sequence
             <220>
      1118
      1119
             <223> Description of Artificial Sequence: Product of
      1120
                    synthesis based on mouse claudin-2 sequence
      1121
             <220>
      1122
             <223> Cyclic Peptide
      1123
             <400> 161
      1124
                   Trp Arg Thr Ser Ser Tyr
E--> 1125
                                      5
             <210> 162
      1126
      1127
             <211> 7
      1128
             <212> PRT
      1129
             <213> Artificial Sequence
      1130
             <220>
      1131
             <223> Description of Artificial Sequence: Product of
      1132
                   synthesis based on mouse claudin-2 sequence
      1133
             <220>
      1134
             <223> Cyclic Peptide
      1135
             <400> 162
      1136
                   Trp Arg Thr Ser Ser Tyr Val
E--> 1137
                                      5
      1138
             <210> 163
             <211> 8
      1139
      1140
             <212> PRT
      1141
             <213> Artificial Sequence
      1142
             <220>
      1143
             <223> Description of Artificial Sequence: Product of
      1144
                   synthesis based on mouse claudin-2 sequence
      1145
             <220>
      1146
             <223> Cyclic Peptide
             <400> 163
      1147
      1148
                   Trp Arg Thr Ser Ser Tyr Val Gly
     1149
```

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

```
<210> 164
      1150
      1151
             <211> 6
      1152
             <212> PRT
             <213> Artificial Sequence
      1153
      1154
             <220>
      1155
             <223> Description of Artificial Sequence: Product of
      1156
                    synthesis based on human, mouse and monkey CPE-R
                    sequences
      1157
      1158
             <220>
      1159
             <223> Cyclic Peptide
             <400> 164
      1160
                    Cys Val Thr Ala Phe Cys
      1161
E-->
      1162
                      1
                                       5
             <210> 165
      1163
      1164
             <211> 7
      1165
             <212> PRT
             <213> Artificial Sequence
      1166
      1167
      1168
             <223> Description of Artificial Sequence: Product of
      1169
                    synthesis based on human, mouse and monkey CPE-R
      1170
                    sequences
      1171
             <220>
      1172
             <223> Cyclic Peptide
      1173
             <400> 165
      1174
                    Cys Val Thr Ala Phe Ile Cys
      1175
E-->
                                       5
             <210> 166
      1176
      1177
             <211> 8
      1178
             <212> PRT
      1179
             <213> Artificial Sequence
      1180
             <220>
      1181
             <223> Description of Artificial Sequence: Product of
      1182
                   synthesis based on human, mouse and monkey CPE-R
      1183
                   sequences
      1184
             <220>
      1185
             <223> Cyclic Peptide
      1186
             <400> 166
      1187
                   Cys Val Thr Ala Phe Ile Gly Cys
      1188
                                      5
      1189
             <210> 167
      1190
             <211> 7
      1191
             <212> PRT
      1192
             <213> Artificial Sequence
      1193
             <220>
      1194
             <223> Description of Artificial Sequence: Product of
      1195
                   synthesis based on human, mouse and monkey CPE-R
```

DATE: 11/12/1998 RAW SEQUENCE LISTING PAGE: 27 PATENT APPLICATION US/09/185,908 TIME: 17:06:06

					input bost illustration
	1106		comiencer		
	1196	-000	sequences		
	1197	<220>	munitu mantida		
	1198		Cyclic Peptide		
	1199	<400>		la Dha Crea	0.1
_	1200		Cys Arg Val Thr A	5	1101
E>	1201		1	<u> </u>	
	1202	<210>	168		_
	1203	<211>			
	1204	<212>			
	1205		Artificial Sequen	ce	
	1206	<220>			
	1207		Description of Ar	tificial Sequence:	Product of
	1208	10007		n human, mouse and	
	1209		sequences	,	•
	1210	<220>			
	1210		Cyclic Peptide		
	1211	<400>	<del>-</del>		
	1212		Cys Arg Val Thr A	la Phe Ile Cvs	$\sim$
P .	1213		1	5	/ ₁₀ P
<u>&gt;</u>	1214		<b>-</b>		
	1215	<210>	169		
	1216	<211>			
	1217	<212>			
	1217		Artificial Sequen	ce	
	1219	<220>	merriorar boques		
	1220		Description of Ar	tificial Sequence:	Product of
	1221	12237		n human, mouse and	
	1222		sequences		
	1223	<220>	bequences		
	1224		Cyclic Peptide		
	1225	<400>			
	1225	(400)		la Phe Ile Gly Cys	$\sim 1$
E>	1227		1	5	60 7
E>	1221		<b>-</b>	<b>.</b>	
	1228	<210>	170		
	1229	<211>			
	1230	<212>			
	1231		Artificial Sequen	ce	
	1232	<220>	_		
	1233		Description of Ar	tificial Sequence:	Product of
	1234			n human, mouse and	
	1235		sequences		
	1236	<220>			
	1237		Cyclic Peptide		
	1238	<400>			<b>^</b> 1
	1239	- 100/	Cys Trp Arg Val T	hr Ala Phe Cvs	/ \J
R>	1240		1	5	40/
					<u></u>
	1241	<210>	171		

DATE: 11/12/1998 RAW SEQUENCE LISTING PAGE: 28 TIME: 17:06:06

PATENT APPLICATION US/09/185,908

```
<211> 9
      1242
             <212> PRT
      1243
             <213> Artificial Sequence
      1244
      1245
             <220>
             <223> Description of Artificial Sequence: Product of
      1246
                   synthesis based on human, mouse and monkey CPE-R
      1247
                   sequences
      1248
             <220>
      1249
      1250
             <223> Cyclic Peptide
             <400> 171
      1251
                   Cys Trp Arg Val Thr Ala Phe Ile Cys
      1252
                                      5
E-->
      1253
             <210> 173
      1254
      1255
             <211> 6
             <212> PRT
      1256
             <213> Artificial Sequence
      1257
             <220>
      1258
             <223> Description of Artificial Sequence: Product of
      1259
                    synthesis based on human, mouse and monkey CPE-R
      1260
                    sequences
      1261
      1262
             <220>
             <223> Cyclic Peptide
      1263
      1264
             <400> 173
                   Lys Val Thr Ala Phe Asp
      1265
                                       5
      1266
      1267
             <210> 174
             <211> 7
      1268
      1269
             <212> PRT
      1270
             <213> Artificial Sequence
      1271
              <220>
              <223> Description of Artificial Sequence: Product of
      1272
                    synthesis based on human, mouse and monkey CPE-R
      1273
                    sequences
      1274
      1275
              <220>
              <223> Cyclic Peptide
      1276
              <400> 174
      1277
                    Lys Val Thr Ala Phe Ile Asp
      1278
     1279
E-->
              <210> 175
      1280
      1281
              <211> 8
              <212> PRT
      1282
              <213> Artificial Sequence
      1283
      1284
              <220>
              <223> Description of Artificial Sequence: Product of
      1285
                    synthesis based on human, mouse and monkey CPE-R
      1286
      1287
                    sequences
      1288
              <220>
```

OIPE

DATE: 11/12/1998 TIME: 17:06:06 RAW SEQUENCE LISTING PAGE: 29

PATENT APPLICATION US/09/185,908

			<del>-</del>
	1289	<223>	Cyclic Peptide
	1290	<400>	175
	1291		Lys Val Thr Ala Phe Ile Gly Asp $\bigcap \int$
E>	1292		1 5 (10)
	1293	<210>	176
	1294	<211>	
	1295	<212>	
	1296		Artificial Sequence
	1297	<220>	
	1298		Description of Artificial Sequence: Product of
	1299		synthesis based on human, mouse and monkey CPE-R
	1300		sequences
	1301	<220>	<del>-</del>
	1302	<223>	Cyclic Peptide
	1303	<400>	
	1304		Lys Arg Val Thr Ala Phe Asp
E>	1305		1 5 (10) ^y
			<del>\</del>
	1306	<210>	177
	1307	<211>	8
	1308	<212>	PRT
	1309	<213>	Artificial Sequence
	1310	<220>	
	1311	<223>	Description of Artificial Sequence: Product of
	1312		synthesis based on human, mouse and monkey CPE-R
	1313		sequences
	1314	<220>	
	1315		Cyclic Peptide
	1316	<400>	
_	1317		Lys Arg Val Thr Ala Phe Ile Asp
E>	1318		1 5 (10)
<del></del>	1319	<210>	178
	1320	<211>	9
	1321	<212>	PRT
	1322	<213>	Artificial Sequence
	1323	<220>	
	1324	<223>	Description of Artificial Sequence: Product of
	1325		synthesis based on human, mouse and monkey CPE-R
	1326		sequences
	1326 1327	<220>	sequences
			Cyclic Peptide
	1327		Cyclic Peptide 178
	1327 1328	<223>	Cyclic Peptide
E>	1327 1328 1329	<223>	Cyclic Peptide 178
E>	1327 1328 1329 1330 1331	<223> <400>	Cyclic Peptide 178 Lys Arg Val Thr Ala Phe Ile Gly Asp 1 5
E>	1327 1328 1329 1330	<223>	Cyclic Peptide 178 Lys Arg Val Thr Ala Phe Ile Gly Asp 1 5 (10)

DATE: 11/12/1998 RAW SEQUENCE LISTING PAGE: 30 TIME: 17:06:06

PATENT APPLICATION US/09/185,908

	1335	<213>	Artificial Sequence
	1336	<220>	
	1337	<223>	Description of Artificial Sequence: Product of
	1338		synthesis based on human, mouse and monkey CPE-R
	1339		sequences
	1340	<220>	
	1341	<223>	Cyclic Peptide
	1342	<400>	
	1343		Lys Trp Arg Val Thr Ala Phe Asp
E>	1344		1 5 40 5
<del></del>			
	1345	<210>	180
	1346	<211>	9
	1347	<212>	PRT
	1348	<213>	Artificial Sequence
	1349	<220>	
	1350	<223>	Description of Artificial Sequence: Product of
	1351		synthesis based on human, mouse and monkey CPE-R
	1352		sequences
	1353	<220>	
	1354	<223>	Cyclic Peptide
	1355	<400>	
	1356		Lys Trp Arg Val Thr Ala Phe Ile Asp $\bigcap$ $\int$
E>	1357		1 5 $(10)$
	1358	<210>	
	1359	<211>	6
	1359 1360	<211> <212>	6 PRT
	1359 1360 1361	<211> <212> <213>	6 PRT Artificial Sequence
	1359 1360 1361 1362	<211><212><213><220>	6 PRT Artificial Sequence
	1359 1360 1361 1362 1363	<211><212><213><220>	PRT Artificial Sequence  Description of Artificial Sequence: Product of
	1359 1360 1361 1362 1363 1364	<211><212><213><220>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R
	1359 1360 1361 1362 1363 1364 1365	<211><212><213><220><223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences
	1359 1360 1361 1362 1363 1364 1365 1366	<211> <212> <213> <220> <223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences
	1359 1360 1361 1362 1363 1364 1365 1366	<211><212><213><220><223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide
	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368	<211> <212> <213> <220> <223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182
	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369	<211><212><213><220><223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368	<211><212><213><220><223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370	<211> <212> <213> <220> <223>  <220> <223>  <400>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370	<211> <212> <213> <220> <223> <220> <223> <400>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5 10
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370	<211> <212> <213> <220> <223> <220> <223> <400> <211>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370	<211> <212> <213> <220> <223> <220> <223> <400> <211> <211> <212>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370	<211> <212> <213> <220> <223> <220> <223> <210> <221> <211> <211> <211>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide  182 Lys Val Thr Ala Phe Glu  1 5 10  183  7 PRT Artificial Sequence
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370	<211> <212> <213> <220> <223> <220> <223> <221> <211> <211> <212> <213> <220>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5 10  183 7 PRT Artificial Sequence
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376	<211> <212> <213> <220> <223> <220> <223> <221> <211> <211> <212> <213> <220>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5  183 7 PRT Artificial Sequence  Description of Artificial Sequence: Product of
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1370 1371 1372 1373 1374 1375 1376 1377	<211> <212> <213> <220> <223> <220> <223> <221> <211> <211> <212> <213> <220>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5  183 7 PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1370 1371 1372 1373 1374 1375 1376 1377	<211> <212> <213> <220> <223> <220> <223> <400> <211> <212> <211> <212> <213>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5  183 7 PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377	<211> <212> <213> <220> <223> <220> <223> <400>  <211> <212> <211> <212> <213> <220> <223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide 182 Lys Val Thr Ala Phe Glu 1 5  183 7 PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences
E>	1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1370 1371 1372 1373 1374 1375 1376 1377	<211> <212> <213> <220> <223> <220> <223> <400>  <211> <212> <211> <212> <213> <220> <223>	PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide  182 Lys Val Thr Ala Phe Glu  1 5  183  7 PRT Artificial Sequence  Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R sequences  Cyclic Peptide

### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998

TIME: 17:06:06

E>	1382 1383	Lys Val Thr Ala Phe Ile Glu
	1363	
	1384	<210> 184
	1385	<211> 8
	1386	<212> PRT
	1387	<213> Artificial Sequence
	1388	<220>
	1389	<223> Description of Artificial Sequence: Product of
	1390	synthesis based on human, mouse and monkey CPE-R
	1391	sequences
	1392	<220>
	1393	<223> Cyclic Peptide
	1394	<400> 184
	1395	Lys Val Thr Ala Phe Ile Gly Glu
E>	1396	1 5 $\binom{10}{}$
	1207	<210> 185
	1397	<210> 165 <211> 7
	1398 1399	<211> / <212> PRT
	1400	<213> Artificial Sequence
	1400	<220>
	1401	<223> Description of Artificial Sequence: Product of
	1402	synthesis based on human, mouse and monkey CPE-R
	1404	sequences
	1405	<220>
	1406	<223> Cyclic Peptide
	1407	<400> 185
	1408	Lys Arg Val Thr Ala Phe Glu
E>	1409	$\frac{1}{1}$ 5 $\frac{10}{10}$
-	<u> </u>	
	1410	<210> 186
	1411	<211> 8
	1412	<212> PRT
	1413	<213> Artificial Sequence
	1414	<220>
	1415	<223> Description of Artificial Sequence: Product of
	1416	synthesis based on human, mouse and monkey CPE-R
	1417	sequences
	1418	<220>
	1419	<223> Cyclic Peptide
	1420	<400> 186
_	1421	Lys Arg Val Thr Ala Phe Ile Glu
E>	1422	1 5
	1423	<210> 187
	1424	<211> 9
	1425	<212> PRT
	1426	<213> Artificial Sequence
	1427	<220>
		· · · ·

DATE: 11/12/1998 RAW SEQUENCE LISTING PAGE: 32 TIME: 17:06:06 PATENT APPLICATION US/09/185,908 Input Set: I185908.RAW <223> Description of Artificial Sequence: Product of 1428 synthesis based on human, mouse and monkey CPE-R 1429 sequences 1430 <220> 1431 <223> Cyclic Peptide 1432 1433 <400> 187 Lys Arg Val Thr Ala Phe Ile Gly Glu 1434 E--> 1435 1436 <210> 188 <211> 8 1437 <212> PRT 1438 <213> Artificial Sequence 1439 <220> 1440 <223> Description of Artificial Sequence: Product of 1441 synthesis based on human, mouse and monkey CPE-R 1442 1443 sequences 1444 <220> <223> Cyclic Peptide 1445 <400> 188 1446 Lys Trp Arg Val Thr Ala Phe Glu 1447 5 E--> 1448 1449 <210> 189 <211> 9 1450 <212> PRT 1451 1452 <213> Artificial Sequence 1453 <223> Description of Artificial Sequence: Product of 1454 synthesis based on human, mouse and monkey CPE-R 1455 sequences 1456 <220> 1457 <223> Cyclic Peptide 1458

E>	1461	1	5	(10)
	1462	<210> 191		
	1463	<211> 6		
	1464	<212> PRT		
	1465	<213> Artific	cial Sequence	
	1466	<220>		
	1467			Sequence: Product of
	1468	synthe	sis based on human,	mouse and monkey CPE-R
	1469	sequen	ces	
	1470	<220>		
	1471	<223> Cyclic	Peptide	
	1472	<400> 191		
	1473	Asp Va	l Ala Thr Phe Lys	$\bigcap$
E>	1474	1	5	(10)

Lys Trp Arg Val Thr Ala Phe Ile Glu

<400> 189

1459

1460

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

-----

```
<210> 192
      1475
             <211> 7
      1476
      1477
             <212> PRT
             <213> Artificial Sequence
      1478
      1479
             <223> Description of Artificial Sequence: Product of
      1480
                   synthesis based on human, mouse and monkey CPE-R
      1481
      1482
                    sequences
             <220>
      1483
             <223> Cyclic Peptide
      1484
      1485
             <400> 192
                   Asp Val Thr Ala Phe Ile Lys
      1486
                                       5
      1487
E-->
             <210> 193
      1488
             <211> 8
      1489
             <212> PRT
      1490
             <213> Artificial Sequence
      1491
      1492
             <220>
             <223> Description of Artificial Sequence: Product of
      1493
                    synthesis based on human, mouse and monkey CPE-R
      1494
      1495
                    sequences
             <220>
      1496
             <223> Cyclic Peptide
      1497
      1498
             <400> 193
                    Asp Val Thr Ala Phe Ile Gly Lys
      1499
                                       5
      1500
E-->
             <210> 194
      1501
             <211> 7
      1502
              <212> PRT
      1503
             <213> Artificial Sequence
      1504
      1505
             <220>
              <223> Description of Artificial Sequence: Product of
      1506
                    synthesis based on human, mouse and monkey CPE-R
      1507
                    sequences
      1508
             <220>
      1509
      1510
              <223> Cyclic Peptide
              <400> 194
      1511
                    Asp Arg Val Thr Ala Phe Lys
      1512
                                       5
     1513
                      1
E-->
      1514
              <210> 195
      1515
              <211> 8
              <212> PRT
      1516
      1517
             <213> Artificial Sequence
      1518
              <220>
              <223> Description of Artificial Sequence: Product of
      1519
                    synthesis based on human, mouse and monkey CPE-R
      1520
```

DATE: 11/12/1998 RAW SEQUENCE LISTING PAGE: 34 TIME: 17:06:06

PATENT APPLICATION US/09/185,908

1521 sequences 1522 <220> 1523 <223> Cyclic Peptide 1524 <400> 195 1525 Asp Arg Val Thr Ala Phe Ile Lys 1527 <210> 196 1528 <211> 9 1529 <212> PRT 1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of synthesis based on human, mouse and monkey CPE-R 1536 <220> 1536 <220> 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1522 <220> 1523 <223> Cyclic Peptide 1524 <400> 195 1525	
1523	
1524 <400> 195 1525 Asp Arg Val Thr Ala Phe Ile Lys 1526 1 5  1527 <210> 196 1528 <211> 9 1529 <212> PRT 1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	2
E> 1526	<u> </u>
E> 1526 1 5 (10)  1527 <210> 196 1528 <211> 9 1529 <212> PRT 1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	2
1527 <210> 196 1528 <211> 9 1529 <212> PRT 1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1528 <211> 9 1529 <212> PRT 1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1528 <211> 9 1529 <212> PRT 1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	<b>S</b>
1529 <212> PRT 1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	2
1530 <213> Artificial Sequence 1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	2
1531 <220> 1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	٤
1532 <223> Description of Artificial Sequence: Product of 1533 synthesis based on human, mouse and monkey CPE-R 1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
synthesis based on human, mouse and monkey CPE-R sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1534 sequences 1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1535 <220> 1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1536 <223> Cyclic Peptide 1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1537 <400> 196 1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
1538 Asp Arg Val Thr Ala Phe Ile Gly Lys	
la a P	
E> 1539 1 5	
1540 <210> 197	
1541 <211> 8	
1541 <211> 6 1542 <212> PRT	
1542 <212> FRI 1543 <213> Artificial Sequence	
1544 <220>	
1544 <2207 1545 <223> Description of Artificial Sequence: Product of	
1546 synthesis based on human, mouse and monkey CPE-F	8
1547 sequences	
1547 sequences 1548 <220>	
_ / 1.00	
E> 1552 1 5	
1553 <210> 198	
1554 <211> 9	
1555 <212> PRT	
1556 <213> Artificial Sequence o	
1557 <220>	
1558 <223> Description of Artificial Sequence: Product of	
1559 synthesis based on human, mouse and monkey CPE-F	₹
1560 sequences	
1561 <220>	
1562 <223> Cyclic Peptide	
1563 <400> 198	
1564 Asp Trp Arg Val Thr Ala Phe Ile Lys /	
E> 1565 1 5 (10)	

DATE: 11/12/1998 RAW SEQUENCE LISTING PAGE: 35 TIME: 17:06:06

PATENT APPLICATION US/09/185,908

```
<211> 6
     1567
             <212> PRT
     1568
             <213> Artificial Sequence
     1569
     1570
             <220>
             <223> Description of Artificial Sequence: Product of
     1571
                   synthesis based on human, mouse and monkey CPE-R
     1572
                   sequences
      1573
             <220>
     1574
     1575
             <223> Cyclic Peptide
             <400> 200
      1576
                   Glu Val Thr Ala Phe Lys
      1577
                                      5
     1578
             <210> 201
      1579
             <211> 7
      1580
             <212> PRT
      1581
             <213> Artificial Sequence
      1582
             <220>
      1583
             <223> Description of Artificial Sequence: Product of
      1584
                   synthesis based on human, mouse and monkey CPE-R
      1585
                   sequences
      1586
             <220>
      1587
             <223> Cyclic Peptide
      1588
             <400> 201
      1589
      1590
                   Glu Val Thr Ala Phe Ile Lys
                                      5
     1591
E-->
             <210> 202
      1592
             <211> 8
      1593
             <212> PRT
      1594
             <213> Artificial Sequence
      1595
      1596
             <220>
             <223> Description of Artificial Sequence: Product of
      1597
                   synthesis based on human, mouse and monkey CPE-R
      1598
      1599
                   sequences
      1600
             <220>
             <223> Cyclic Peptide
      1601
      1602
             <400> 202
                   Glu Val Thr Ala Phe Ile Gly Lys
      1603
E--> 1604
             <210> 203
      1605
             <211> 7
      1606
             <212> PRT
      1607
      1608
             <213> Artificial Sequence
      1609
             <220>
             <223> Description of Artificial Sequence: Product of
      1610
                   synthesis based on human, mouse and monkey CPE-R
      1611
                   sequences
      1612
      1613
             <220>
```

DATE: 11/12/1998 PAGE: 36 RAW SEQUENCE LISTING TIME: 17:06:06

PATENT APPLICATION US/09/185,908

							input bee. 1100500:lain
				•			
	1614		Cyclic Pepti	ae			
	1615	<400>		-1	-1 -	^ <i>1</i>	
_	1616		Glu Arg Val		Pne Lys	( ) )	
E>	1617		1	5		(19)	
	1610	-210>	204				
	1618	<210>					
	1619	<211>					
	1620	<212>					
	1621		Artificial S	equence			
	1622	<220>		<b>.</b>			
	1623	<223>	_		ficial Sequence:		
	1624			sed on h	numan, mouse and	monkey CPE-	R
	1625		sequences				
	1626	<220>					
	1627		Cyclic Pepti	.de			
	1628	<400>				- 1	
	1629		Glu Arg Val	Thr Ala	Phe Ile Lys		
E>	1630		1	5		(10)~	
	1631	<210>					
	1632	<211>					
	1633	<212>					
	1634		Artificial S	equence			
	1635	<220>		· 1 ·			
	1636	<223>	_		ficial Sequence:		
	1637		-	sed on h	numan, mouse and	monkey CPE-	R
	1638		sequences				
	1639	<220>					
	1640		Cyclic Pepti	de			
	1641	<400>				$\sim$ $\sim$	
	1642		_		Phe Ile Gly Lys	: <i>)</i>	
E>	1643		1	5		(10)	
	1644	<210>	226				
	1644						
	1645	<211><212>					
	1646						
	1647		Artificial S	equence			
	1648	<220>	Dogaristics	of 3-1-4	idial Companda	Drodust of	
	1649	<223>	_		ficial Sequence:		
	1650		-	seu on r	numan, mouse and	monkey CPE-	K
	1651	-000	sequences				
	1652	<220>	Granda Brest				
	1653		Cyclic Pepti	ae			
	1654	<400>			ale phe see	$\cap$ 1	
_	1655		Glu Trp Arg		Ala Phe Lys	الأدرا	
E>	1656		1	5		$\epsilon_0$	
	1657	<210>	207				
	1658	<211>					
	1659	<211>					
	1033	<212>	FKI				

TIME: 17:06:06

PAGE: 37 RAW SEQUENCE LISTING DATE: 11/12/1998

PATENT APPLICATION US/09/185,908

```
1660
              <213> Artificial Sequence
      1661
              <220>
      1662
              <223> Description of Artificial Sequence: Product of
      1663
                    synthesis based on human, mouse and monkey CPE-R
      1664
                    sequences
      1665
              <220>
      1666
              <223> Cyclic Peptide
      1667
              <400> 207
      1668
                    Glu Trp Arg Val Thr Ala Phe Ile Lys
E-->
     1669
                                       5
      1670
              <210> 209
      1671
             <211> 5
              <212> PRT
      1672
      1673
             <213> Artificial Sequence
      1674
             <220>
      1675
             <223> Description of Artificial Sequence: Product of
      1676
                    synthesis based on human, mouse and monkey CPE-R
      1677
                    sequences
      1678
             <220>
      1679
             <223> Cyclic Peptide
      1680
             <400> 209
                    Val Thr Ala Phe Ile
      1681
E-->
      1682
      1683
             <210> 210
      1684
             <211> 6
      1685
             <212> PRT
      1686
             <213> Artificial Sequence
      1687
             <220>
      1688
             <223> Description of Artificial Sequence: Product of
                    synthesis based on human, mouse and monkey CPE-R
      1689
      1690
                    sequences
      1691
             <220>
      1692
             <223> Cyclic Peptide
      1693
             <400> 210
      1694
                   Val Thr Ala Phe Ile Gly
E-->
     1695
                     1
                                      5
      1696
             <210> 211
      1697
             <211> 5
      1698
             <212> PRT
      1699
             <213> Artificial Sequence
      1700
      1701
             <223> Description of Artificial Sequence: Product of
      1702
                   synthesis based on human, mouse and monkey CPE-R
      1703
                   sequences
      1704
             <220>
      1705
             <223> Cyclic Peptide
      1706
             <400> 211
```

### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

		Input 500. IIO5500.IA
	1707	Arg Val Thr Ala Phe $\int j$
E>	1708	1 5 (10)
_		
	1709	210> 212
	1710	2211> 6
	1711	212> PRT
	1712	213> Artificial Sequence
	1713	:220>
	1714	223> Description of Artificial Sequence: Product of
	1715	synthesis based on human, mouse and monkey CPE-R
	1716	sequences
	1717	220>
	1718	223> Cyclic Peptide
	1719	400> 212
	1720	Arg Val Thr Ala Phe Ile
E>	1721	1 5 (10)
	1722	210> 213
	1723	211> 7
	1724	212> PRT
	1725	213> Artificial Sequence
	1726	220>
	1727	223> Description of Artificial Sequence: Product of
	1728	synthesis based on human, mouse and monkey CPE-R
	1729	sequences
	1730	220>
	1731	223> Cyclic Peptide
	1732	400> 213
_	1733	Arg Val Thr Ala Phe Ile Gly
E>	1734	1 5 (10)
	1825	
	1735	210> 214
	1736	211> 6
	1737	212> PRT
	1738	213> Artificial Sequence
	1739	220>
	1740	223> Description of Artificial Sequence: Product of
	1741	synthesis based on human, mouse and monkey CPE-R
	1742	sequences
	1743	220>
	1744	223> Cyclic Peptide
	1745	100> 214
<b>15</b> 1	1746	Trp Arg Val Thr Ala Phe
E>	1747	1 5 (10)
	1740	010. 015
	1748	210> 215
	1749	211> 7
	1750	212> PRT
	1751	213> Artificial Sequence
	1752	20>

PAGE: 39 RAW SEQUENCE LISTING DATE: 11/12/1998

PATENT APPLICATION US/09/185,908

TIME: 17:06:06

Input Set: I185908.RAW <223> Description of Artificial Sequence: Product of 1753 1754 synthesis based on human, mouse and monkey CPE-R 1755 sequences 1756 <220> 1757 <223> Cyclic Peptide 1758 <400> 215 1759 Trp Arg Val Thr Ala Phe Ile 1760 1761 <210> 216 1762 <211> 8 1763 <212> PRT <213> Artificial Sequence 1764 1765 <220> 1766 <223> Description of Artificial Sequence: Product of 1767 synthesis based on human, mouse and monkey CPE-R 1768 sequences 1769 <220> 1770 <223> Cyclic Peptide <400> 216 1771 1772 Trp Arg Val Thr Ala Phe Ile Gly E--> 1773 5 1774 <210> 217 1775 <211> 6 1776 <212> PRT 1777 <213> Artificial Sequence 1778 <220> 1779 <223> Description of Artificial Sequence: Product of synthesis based on human and rat RVP-1 sequences 1780 1781 <220> 1782 <223> Cyclic Peptide 1783 <400> 217 1784 Cys Val Ser Ala Phe Cys 1785 E--> 5 1786 <210> 218 1787 <211> 7 1788 <212> PRT 1789 <213> Artificial Sequence 1790 <220> 1791 <223> Description of Artificial Sequence: Product of 1792 synthesis based on human and rat RVP-1 sequences 1793 <220>

1798 <210> 219

<400> 218

1794 1795

1796

1797

<223> Cyclic Peptide

1

Cys Val Ser Ala Phe Ile Cys

5

PAGE: 40 RAW SEQUENCE LISTING DATE: 11/1

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/185,908

Input Set: I185908.RAW

DATE: 11/12/1998

TIME: 17:06:06

1799 <211> 8 1800 <212> PRT 1801 <213> Artificial Sequence 1802 <220> 1803 <223> Description of Artificial Sequence: Product of 1804 synthesis based on human and rat RVP-1 sequences 1805 <220> <223> Cyclic Peptide 1806 <400> 219 1807 1808 Cys Val Ser Ala Phe Ile Gly Cys 1809 E--> 1810 <210> 220 1811 <211> 7 1812 <212> PRT <213> Artificial Sequence 1813 1814 <220> 1815 <223> Description of Artificial Sequence: Product of 1816 synthesis based on human and rat RVP-1 sequences 1817 <220> 1818 <223> Cyclic Peptide 1819 <400> 220 1820 Cys Arg Val Ser Ala Phe Cys 1821 E--> 5 1822 <210> 221 1823 <211> 8 1824 <212> PRT 1825 <213> Artificial Sequence 1826 <220> 1827 <223> Description of Artificial Sequence: Product of 1828 synthesis based on human and rat RVP-1 sequences 1829 <220> 1830 <223> Cyclic Peptide 1831 <400> 221 1832 Cys Arg Val Ser Ala Phe Ile Cys E--> 1833 5 1834 <210> 222 1835 <211> 9 1836 <212> PRT 1837 <213> Artificial Sequence <220> 1838 1839 <223> Description of Artificial Sequence: Product of 1840 synthesis based on human and rat RVP-1 sequences 1841 <220> 1842 <223> Cyclic Peptide 1843 <400> 222 1844 Cys Arg Val Ser Ala Phe Ile Gly Cys 1845

### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

```
1846
              <210> 223
       1847
              <211> 8
       1848
              <212> PRT
       1849
              <213> Artificial Sequence
       1850
              <220>
      1851
              <223> Description of Artificial Sequence: Product of
       1852
                    synthesis based on human and rat RVP-1 sequences
      1853
              <220>
      1854
              <223> Cyclic Peptide
      1855
              <400> 223
      1856
                    Cys Trp Arg Val Ser Ala Phe Cys
E-->
      1857
      1858
              <210> 224
      1859
              <211> 9
      1860
              <212> PRT
      1861
              <213> Artificial Sequence
      1862
              <220>
      1863
              <223> Description of Artificial Sequence: Product of
      1864
                    synthesis based on human and rat RVP-1 sequences
      1865
              <220>
      1866
             <223> Cyclic Peptide
      1867
              <400> 224
      1868
                    Cys Trp Arg Val Ser Ala Phe Ile Cys
E-->
      1869
                                       5
      1870
             <210> 226
      1871
             <211> 6
             <212> PRT
      1872
      1873
             <213> Artificial Sequence
      1874
             <223> Description of Artificial Sequence: Product of
      1875
                    synthesis based on human and rat RVP-1 sequences
      1876
      1877
             <220>
      1878
             <223> Cyclic Peptide
      1879
             <400> 226
      1880
                   Lys Val Ser Ala Phe Asp
      1881
E-->
                     1
                                      5
      1882
             <210> 227
      1883
             <211> 7
      1884
             <212> PRT
      1885
             <213> Artificial Sequence
      1886
             <220>
      1887
             <223> Description of Artificial Sequence: Product of
      1888
                   synthesis based on human and rat RVP-1 sequences
      1889
             <220>
      1890
             <223> Cyclic Peptide
      1891
             <400> 227
```

## RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

	1892		Two Wal Cam Bla Dha Tla I	
B>	1893		Lys Val Ser Ala Phe Ile A	Asp
			<u> </u>	
	1894	<210>	> 228	
	1895	<211>	· 8	
	1896	<212>		
	1897		Artificial Sequence	
	1898	<220>	<del></del>	
	1899		Description of Artificial	Sequence: Product of
	1900	12207	synthesis based on human	
	1901	<220>		and lac kvr i bequences
	1902		· Cyclic Peptide	
	1903	<400>		
	1904	11007	Lys Val Ser Ala Phe Ile G	alv Aen )
E>	1905		1 5	ary Asp
	1906	<210>	. 229	
	1907	<211>		
	1908	<212>		
	1909		Artificial Sequence	
	1910	<220>		
	1911		Description of Artificial	Seguence: Product of
	1912	12237	synthesis based on human	
	1913	<220>		and lat kvr-1 sequences
	1914		Cyclic Peptide	
	1915	<400>		
	1916	(100)	Lys Arg Val Ser Ala Phe A	Jen O
E>	1917		1 5	10 1
	1918	<210>	230	
	1919	<211>		
	1920	<212>	PRT	
	1921		Artificial Sequence	
	1922	<220>	<del>-</del>	
	1923	<223>	Description of Artificial	Sequence: Product of
	1924		synthesis based on human	
	1925	<220>		
	1926	<223>	Cyclic Peptide	
	1927	<400>	<del>-</del>	
	1928		Lys Arg Val Ser Ala Phe I	le Asp
E>	1929		1 5	101
		<del></del>		
	1930	<210>	231	•
	1931	<211>	9	
	1932	<212>	PRT	
	1933	<213>	Artificial Sequence	
	1934	<220>	-	
	1935	<223>	Description of Artificial	Sequence: Product of
	1936		synthesis based on human a	
	1937	<220>		-

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

```
<223> Cyclic Peptide
       1939
              <400> 231
       1940
                    Lys Arg Val Ser Ala Phe Ile Gly Asp
      1941
       1942
              <210> 232
      1943
              <211> 8
      1944
              <212> PRT
      1945
              <213> Artificial Sequence
      1946
              <220>
              <223> Description of Artificial Sequence: Product of
      1947
                    synthesis based on human and rat RVP-1 sequences
      1948
      1949
              <220>
              <223> Cyclic Peptide
      1950
      1951
              <400> 232
      1952
                    Lys Trp Arg Val Ser Ala Phe Asp
      1953
E-->
                                       5
      1954
              <210> 233
      1955
              <211> 9
      1956
              <212> PRT
      1957
              <213> Artificial Sequence
      1958
              <220>
              <223> Description of Artificial Sequence: Product of
      1959
      1960
                    synthesis based on human and rat RVP-1 sequences
      1961
              <220>
      1962
             <223> Cyclic Peptide
      1963
             <400> 233
      1964
                    Lys Trp Arg Val Ser Ala Phe Ile Asp
E--> 1965
      1966
             <210> 235
      1967
             <211> 6
      1968
             <212> PRT
      1969
             <213> Artificial Sequence
      1970
      1971
             <223> Description of Artificial Sequence: Product of
      1972
                    synthesis based on human and rat RVP-1 sequences
      1973
             <220>
      1974
             <223> Cyclic Peptide
      1975
             <400> 235
      1976
                   Lys Val Ser Ala Phe Glu
E-->
      1977
                     1
      1978
             <210> 236
      1979
             <211> 7
      1980
             <212> PRT
      1981
             <213> Artificial Sequence
      1982
      1983
             <223> Description of Artificial Sequence: Product of
```

### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

```
1984
                    synthesis based on human and rat RVP-1 sequences
       1985
              <220>
       1986
              <223> Cyclic Peptide
              <400> 236
       1987
       1988
                    Lys Val Ser Ala Phe Ile Glu
E-->
      1989
                                       5
       1990
              <210> 237
              <211> 8
       1991
       1992
              <212> PRT
              <213> Artificial Sequence
       1993
       1994
              <220>
              <223> Description of Artificial Sequence: Product of
       1995
       1996
                    synthesis based on human and rat RVP-1 sequences
       1997
              <220>
      1998
              <223> Cyclic Peptide
       1999
              <400> 237
      2000
                    Lys Val Ser Ala Phe Ile Gly Glu
E-->
      2001
                                       5
      2002
              <210> 238
      2003
              <211> 7
      2004
              <212> PRT
      2005
              <213> Artificial Sequence
      2006
              <220>
      2007
              <223> Description of Artificial Sequence: Product of
      2008
                    synthesis based on human and rat RVP-1 sequences
      2009
              <220>
      2010
              <223> Cyclic Peptide
      2011
              <400> 238
      2012
                    Lys Arg Val Ser Ala Phe Glu
      2013
                      1
                                       5
      2014
             <210> 239
      2015
             <211> 8
      2016
             <212> PRT
      2017
             <213> Artificial Sequence
      2018
             <220>
      2019
             <223> Description of Artificial Sequence: Product of
      2020
                    synthesis based on human and rat RVP-1 sequences
      2021
             <220>
      2022
             <223> Cyclic Peptide
      2023
             <400> 239
      2024
                   Lys Arg Val Ser Ala Phe Ile Glu
E--> 2025
      2026
             <210> 240
      2027
             <211> 9
      2028
             <212> PRT
      2029
             <213> Artificial Sequence
```

OIPE PAGE: 45 RAW SEQUENCE LISTING DATE: 11/12/1998 PATENT APPLICATION US/09/185,908 TIME: 17:06:06 Input Set: I185908.RAW 2030 <220> 2031 <223> Description of Artificial Sequence: Product of 2032 synthesis based on human and rat RVP-1 sequences 2033 <220> 2034 <223> Cyclic Peptide 2035 <400> 240 2036 Lys Arg Val Ser Ala Phe Ile Gly Glu 2037 5 2038 <210> 241 2039 <211> 8 2040 <212> PRT 2041 <213> Artificial Sequence 2042 <220> 2043 <223> Description of Artificial Sequence: Product of 2044 synthesis based on human and rat RVP-1 sequences 2045 <220> 2046 <223> Cyclic Peptide 2047 <400> 241 2048 Lys Trp Arg Val Ser Ala Phe Glu 医--> 2049 2050 <210> 242 2051 <211> 9 2052 <212> PRT 2053 <213> Artificial Sequence 2054 2055 <223> Description of Artificial Sequence: Product of 2056 synthesis based on human and rat RVP-1 sequences 2057 <220> 2058 <223> Cyclic Peptide 2059 <400> 242 2060 Lys Trp Arg Val Ser Ala Phe Ile Glu E--> 2061 5 2062 <210> 244 2063 <211> 6 2064 <212> PRT 2065 <213> Artificial Sequence 2066 <220>

<223> Description of Artificial Sequence: Product of

5

synthesis based on human and rat RVP-1 sequences

2074 <210> 245 2075 <211> 7

<220>

<400> 244

<223> Cyclic Peptide

1

Asp Val Ser Ala Phe Lys

2067

2068

2069

2070

2071

2072

2073

E-->

<210> 249

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

Input Set: I185908.RAW

DATE: 11/12/1998

TIME: 17:06:06

```
2076
              <212> PRT
       2077
              <213> Artificial Sequence
       2078
              <220>
       2079
              <223> Description of Artificial Sequence: Product of
      2080
                    synthesis based on human and rat RVP-1 sequences
      2081
              <220>
      2082
              <223> Cyclic Peptide
              <400> 245
      2083
      2084
                    Asp Val Ser Ala Phe Ile Lys
     2085
E-->
      2086
              <210> 246
      2087
              <211> 8
      2088
              <212> PRT
      2089
              <213> Artificial Sequence
      2090
              <220>
              <223> Description of Artificial Sequence: Product of
      2091
      2092
                    synthesis based on human and rat RVP-1 sequences
      2093
             <220>
      2094
             <223> Cyclic Peptide
      2095
              <400> 246
      2096
                    Asp Val Ser Ala Phe Ile Gly Lys
      2097
E-->
                                       5
      2098
             <210> 247
      2099
             <211> 7
      2100
             <212> PRT
      2101
             <213> Artificial Sequence
      2102
             <220>
      2103
             <223> Description of Artificial Sequence: Product of
      2104
                    synthesis based on human and rat RVP-1 sequences
      2105
             <220>
      2106
             <223> Cyclic Peptide
      2107
             <400> 247
      2108
                    Asp Arg Val Ser Ala Phe Lys
     2109
E-->
                                      5
      2110
             <210> 248
      2111
             <211> 8
      2112
             <212> PRT
      2113
             <213> Artificial Sequence
      2114
      2115
             <223> Description of Artificial Sequence: Product of
      2116
                    synthesis based on human and rat RVP-1 sequences
      2117
             <220>
      2118
             <223> Cyclic Peptide
      2119
             <400> 248
      2120
                   Asp Arg Val Ser Ala Phe Ile Lys
E--> 2121
                                      5
      2122
```

PAGE: 47 RAW SEQUENCE LISTING DATE: 11/12/1998

PATENT APPLICATION US/09/185,908

Input Set: I185908.RAW

TIME: 17:06:06

2123 <211> 9 2124 <212> PRT 2125 <213> Artificial Sequence 2126 <220> <223> Description of Artificial Sequence: Product of 2127 2128 synthesis based on human and rat RVP-1 sequences 2129 <220> 2130 <223> Cyclic Peptide <400> 249 2131 2132 Asp Arg Val Ser Ala Phe Ile Gly Lys 2133 2134 <210> 250 2135 <211> 8 2136 <212> PRT 2137 <213> Artificial Sequence 2138 2139 <223> Description of Artificial Sequence: Product of 2140 synthesis based on human and rat RVP-1 sequences 2141 <220> 2142 <223> Cyclic Peptide 2143 <400> 250 2144 Asp Trp Arg Val Ser Ala Phe Lys E--> 2145 5 2146 <210> 251 2147 <211> 9 2148 <212> PRT 2149 <213> Artificial Sequence 2150 <220> <223> Description of Artificial Sequence: Product of 2151 2152 synthesis based on human and rat RVP-1 sequences 2153 <220> 2154 <223> Cyclic Peptide 2155 <400> 251 2156 Asp Trp Arg Val Ser Ala Phe Ile Lys E--> 2157 2158 <210> 253 2159 <211> 6

2160 <212> PRT

2161 <213> Artificial Sequence

2162 <220>

2163 <223> Description of Artificial Sequence: Product of

2164 synthesis based on human and rat RVP-1 sequences

2165 <220>

2166 <223> Cyclic Peptide

2167 <400> 253

2168 Glu Val Ser Ala Phe Lys

E--> 2169 1 5

(10)

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998

TIME: 17:06:06

```
2170
              <210> 254
              <211> 7
      2171
      2172
              <212> PRT
      2173
              <213> Artificial Sequence
      2174
              <220>
      2175
              <223> Description of Artificial Sequence: Product of
                    synthesis based on human and rat RVP-1 sequences
      2176
      2177
              <220>
      2178
              <223> Cyclic Peptide
      2179
              <400> 254
      2180
                    Glu Val Ser Ala Phe Ile Lys
      2181
E-->
      2182
              <210> 255
      2183
              <211> 8
      2184
              <212> PRT
      2185
             <213> Artificial Sequence
      2186
              <220>
      2187
              <223> Description of Artificial Sequence: Product of
      2188
                    synthesis based on human and rat RVP-1 sequences
      2189
              <220>
             <223> Cyclic Peptide
      2190
      2191
              <400> 255
                    Glu Val Ser Ala Phe Ile Gly Lys
      2192
      2193
E-->
                                       5
      2194
             <210> 256
      2195
             <211> 7
      2196
             <212> PRT
      2197
             <213> Artificial Sequence
      2198
             <220>
             <223> Description of Artificial Sequence: Product of
      2199
      2200
                    synthesis based on human and rat RVP-1 sequences
      2201
             <220>
      2202
             <223> Cyclic Peptide
      2203
             <400> 256
      2204
                   Glu Arg Val Ser Ala Phe Lys
      2205
E-->
                      1
                                      5
      2206
             <210> 257
      2207
             <211> 8
      2208
             <212> PRT
      2209
             <213> Artificial Sequence
      2210
             <220>
      2211
             <223> Description of Artificial Sequence: Product of
      2212
                   synthesis based on human and rat RVP-1 sequences
      2213
             <220>
      2214
             <223> Cyclic Peptide
      2215
             <400> 257
```

### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

Series	
2218 <210> 258 2219	
2219	
2220	
2221	
2222 <220> 2223	
2223   223   2223   Description of Artificial Sequence: Product of synthesis based on human and rat RVP-1 sequences	
2224   Synthesis based on human and rat RVP-1 sequences	
2224   Synthesis based on human and rat RVP-1 sequences	
2225	
2227	
E> 2228 Glu Arg Val Ser Ala Phe Ile Gly Lys  2230	
E> 2229 1 5 5 10  2230	
2230	
2231 <211> 8 2232 <212> PRT 2233 <213> Artificial Sequence 2234 <220> 2235 <223> Description of Artificial Sequence: Product of 236	
2231 <211> 8 2232 <212> PRT 2233 <213> Artificial Sequence 2234 <220> 2235 <223> Description of Artificial Sequence: Product of 236	-
2232	
2233	
2234 <220> 2235 <223> Description of Artificial Sequence: Product of 2236 synthesis based on human and rat RVP-1 sequences 2237 <220> 2238 <223> Cyclic Peptide 2239 <400> 259 2240 Glu Trp Arg Val Ser Ala Phe Lys 2241 1 5  2242 <210> 260 2243 <211> 9 2244 <212> PRT 2245 <213> Artificial Sequence 2246 <220> 2247 <223> Description of Artificial Sequence: Product of 2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
2235	
2236 synthesis based on human and rat RVP-1 sequences  2237 <220> 2238 <223> Cyclic Peptide  2239 <400> 259  2240 Glu Trp Arg Val Ser Ala Phe Lys  E> 2241 1 5  2242 <210> 260  2243 <211> 9  2244 <212> PRT  2245 <213> Artificial Sequence  2246 <220> 2247 <223> Description of Artificial Sequence: Product of  2248 synthesis based on human and rat RVP-1 sequences  2249 <220> 2250 <223> Cyclic Peptide	
2237 <220> 2238 <223> Cyclic Peptide 2239 <400> 259 2240	
2238 <223> Cyclic Peptide 2239 <400> 259 2240	
2239	
E> 2240 Glu Trp Arg Val Ser Ala Phe Lys  2242	
E> 2241 1 5 10  2242 <210> 260 2243 <211> 9 2244 <212> PRT 2245 <213> Artificial Sequence 2246 <220> 2247 <223> Description of Artificial Sequence: Product of 2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
2242 <210> 260 2243 <211> 9 2244 <212> PRT 2245 <213> Artificial Sequence 2246 <220> 2247 <223> Description of Artificial Sequence: Product of 2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
2243 <211> 9 2244 <212> PRT 2245 <213> Artificial Sequence 2246 <220> 2247 <223> Description of Artificial Sequence: Product of 2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
2244 <212> PRT 2245 <213> Artificial Sequence 2246 <220> 2247 <223> Description of Artificial Sequence: Product of 2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
<pre>2245</pre>	
2246 <220> 2247 <223> Description of Artificial Sequence: Product of 2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
<pre>2247 &lt;223&gt; Description of Artificial Sequence: Product of 2248</pre>	
2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
2248 synthesis based on human and rat RVP-1 sequences 2249 <220> 2250 <223> Cyclic Peptide	
2250 <223> Cyclic Peptide	
4	
2251 -400- 260	
2251 <400> 260	
2252 Glu Trp Arg Val Ser Ala Phe Ile Lys	
E> 2253 1 5 (10)	
2254 <210> 262	
2255 <211> 5	
2256 <212> PRT	
2257 <213> Artificial Sequence	
2258 <220>	
2259 <223> Description of Artificial Sequence: Product of	
2260 synthesis based on human and rat RVP-1 sequences	
2261 <220>	

PAGE: 50 RAW SEQUENCE LISTING DATE: 11/12/1998

PATENT APPLICATION US/09/185,908

8 TIME: 17:06:06

```
2262
              <223> Cyclic Peptide
      2263
              <400> 262
      2264
                    Val Ser Ala Phe Ile
E-->
      2265
      2266
              <210> 263
      2267
              <211> 6
      2268
              <212> PRT
      2269
             <213> Artificial Sequence
      2270
              <220>
      2271
              <223> Description of Artificial Sequence: Product of
      2272
                    synthesis based on human and rat RVP-1 sequences
      2273
              <220>
      2274
             <223> Cyclic Peptide
      2275
              <400> 263
      2276
                    Val Ser Ala Phe Ile Gly
E-->
      2277
                                       5
             <210> 264
      2278
      2279
             <211> 5
      2280
             <212> PRT
      2281
             <213> Artificial Sequence
      2282
             <220>
      2283
             <223> Description of Artificial Sequence: Product of
      2284
                    synthesis based on human and rat RVP-1 sequences
      2285
             <220>
      2286
             <223> Cyclic Peptide
      2287
             <400> 264
      2288
                    Arg Val Ser Ala Phe
     2289
      2290
             <210> 265
      2291
             <211> 6
      2292
             <212> PRT
      2293
             <213> Artificial Sequence
      2294
             <220>
      2295
             <223> Description of Artificial Sequence: Product of
      2296
                    synthesis based on human and rat RVP-1 sequences
      2297
             <220>
      2298
             <223> Cyclic Peptide
      2299
             <400> 265
      2300
                   Arg Val Ser Ala Phe Ile
E-->
      2301
                                      5
      2302
             <210> 266
      2303
             <211> 7
      2304
             <212> PRT
             <213> Artificial Sequence
      2305
      2306
      2307
             <223> Description of Artificial Sequence: Product of
```

PAGE: 51 DATE: 11/12/1998 TIME: 17:06:06 RAW SEQUENCE LISTING

PATENT APPLICATION US/09/185,908

					I	nput Set:	1185908.RAW
	2308	synt	hesis based on huma	an and rat	PVP-1 semiences		
	2309	<220>	nebib babea on nam	an and rac	KVI I Sequences		
	2310		ic Peptide				
	2311	<400> 266			1		
	2312		Val Ser Ala Phe Ile	e Glv	<b>∩</b> ≪		
E>		1	5	2	10/		
	2314	<210> 267					
	2315	<211> 6					
	2316	<212> PRT					
	2317	<213> Arti	ficial Sequence				
	2318	<220>					
	2319	<223> Desc	ription of Artific	ial Sequenc	e: Product of		
	2320		hesis based on huma	an and rat	RVP-1 sequences		
	2321	<220>					
	2322	<223> Cycl	ic Peptide				
	2323	<400> 267			- 1		
	2324		Arg Val Ser Ala Phe	e	/ Y		
E>	2325	1	5		μο/		
	2326	<210> 268					
	2327	<211> 7					
	2328	<212> PRT					
	2329		ficial Sequence				
	2330	<220>	bodaomoc				
	2331		ription of Artifici	ial Sequence	e: Product of		
	2332		hesis based on huma				
	2333	<220>			boquonoob		
	2334	<223> Cycl	ic Peptide				
	2335	<400> 268	•				
	2336	Trp 2	Arg Val Ser Ala Phe	e Ile	$\cap$ 1		
E>	2337	1	5		(10)		
	2338	<210> 269					
		<211> 8					
	2340	<212> PRT					
	2341		ficial Sequence				
	2342	<220>	Doquonoo				
	2343		ription of Artifici	ial Semience	e: Product of		
	2344		nesis based on huma	_			
	2345	<220>			Dequemons		
	2346	<223> Cycl:	c Peptide				
	2347	<400> 269	- <u>F</u>				
	2348		Arg Val Ser Ala Phe	e Ile Glv	$\sim 1$		
E>	2349	1	5	1	10		

## VERIFICATION SUMMARY

DATE: 11/12/1998 TIME: 17:06:06 PATENT APPLICATION US/09/185,908

Line	?	Error/Warning				Original	Text	
21	- -	Invalid/Missing	Amino	Doid	Numbering	1		
		Invalid/Missing			•	1	5 5	10 10
		Invalid/Missing			•	1	5	10
		Invalid/Missing			•	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			•	1	5	
		Invalid/Missing			•	1	5	10 10
		Invalid/Missing			-	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			•	1	5	10
		Invalid/Missing			•	1	5	10
		Invalid/Missing			•	1	5	10
		Invalid/Missing			-	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			~	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
477	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			-	1	5	10
513	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
525	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
561	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
573	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
585	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
		Invalid/Missing				1	5	10
609	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10

## VERIFICATION SUMMARY PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 ,908 TIME: 17:06:06

Line	?	Error/Warning				Original	Text	
621	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			-	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			<del>-</del>	1	5	10
		Invalid/Missing			<del>-</del>	1	5	10
		Invalid/Missing			-	1	5	10
		Invalid/Missing			•	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			<del>-</del>	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			=	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			=	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			-	1	5	10
933	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
945	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
957	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
969	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
981	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
993	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
1005	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
1017	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
1053	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
1065	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
1077	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10
		Invalid/Missing			-	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing			_	1	5	10
1214	E	Invalid/Missing	Amino	Acid	Numbering	1	5	10

## VERIFICATION SUMMARY

DATE: 11/12/1998 TIME: 17:06:06 PATENT APPLICATION US/09/185,908

Line	?	Error/Warning		Original	Text	
	-		 		_	
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	•	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing Invalid/Missing	_	1	5	10
		Invalid/Missing Invalid/Missing	•	1	5	10
		•	•	1	5	10
		Invalid/Missing Invalid/Missing	-	1 1	5 5	10
		Invalid/Missing		1	5	10 10
		Invalid/Missing		1	5	10
		Invalid/Missing Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing		1	5	10
		Invalid/Missing		1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing		1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing		1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing		1	5	10
		Invalid/Missing		1	5	10
		Invalid/Missing	_	1	5	10
		Invalid/Missing	-	1	5	10
		Invalid/Missing	_	1	5	10
			-			

# VERIFICATION SUMMARY PATENT APPLICATION US/09/185,908

DATE: 11/12/1998 TIME: 17:06:06

Line	?	Error/Warning				Original	Text	
1869	- ਸ਼	Invalid/Missing	Amino A	cid	Numbering	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			-	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
2001	Ε	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2013	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2025	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2037	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2049	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2061	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2073	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2085	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2097	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2109	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2121	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2133	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2145	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
2157	E	Invalid/Missing	Amino A	Acid	Numbering	1	5	10
		Invalid/Missing			=	1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			•	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing			_	1	5	10
		Invalid/Missing				1	5	10
		Invalid/Missing				1	5	10
2349	E	Invalid/Missing	Amino A	rc10	Numbering	1	5	10